Informations éducatives uniquement. Les utilisations expérimentales peuvent ne pas avoir l'approbation de la FDA. Pas un avis médical ou un plan de traitement.
Retatrutide is an investigational triagonist peptide that acts simultaneously at GLP-1, GIP, and glucagon receptors. Unlike dual agonists such as tirzepatide, its additional activity at the glucagon receptor is thought to contribute to energy expenditure signaling. It is currently being studied in clinical trials for its role in metabolic signaling pathways related to energy regulation, body composition, and glycemic control.
Domaines de recherche
GLP-1 Receptor SignalingResearch investigates retatrutide's agonism at glucagon-like peptide-1 receptors, exploring downstream effects on insulin secretion signaling, appetite-regulating neural pathways, and gastric motility research.
GIP Receptor SignalingStudies examine its activity at glucose-dependent insulinotropic polypeptide (GIP) receptors, including incretin signaling, pancreatic beta-cell function research, and interaction with insulin sensitivity pathways.
Glucagon Receptor SignalingResearchers study its glucagon receptor agonism and its potential role in energy expenditure signaling, hepatic glucose output modulation, and lipolysis-related pathway research — a mechanism that distinguishes it from GLP-1/GIP dual agonists.
Metabolic and Glycemic SignalingClinical research explores retatrutide's effects on blood glucose regulation pathways, insulin resistance signaling, and metabolic rate research in subjects with obesity or type 2 diabetes.
Body Composition ResearchPhase 2 trial data are being analyzed for retatrutide's effects on fat mass reduction, lean mass preservation, and adipose tissue signaling pathways.